Withania somnifera root extract improves catecholamines and physiological abnormalities seen in a Parkinson's disease model mouse

Effects of Ashwagandha (Roots of <i>Withania somnifera</i>) on Neurodegenerative Diseases

“…Ashwagandha extracts also showed ameliorative effects against other neurodegenerative disease models such as Parkinson's disease and Huntington's disease, [55][56][57][58][59][60] suggesting that Ashwagandha may be useful against various neurodegenerative diseases (Table 1). Additionally, a novel drug candidate for spinal cord injury was synthesized as a derivative of constituents of Ashwagandha.…”

“…Further studies of Ashwagandha will probably contribute to resolving an urgent unmet medical need: efficacious treatments that may offer cure of neurodegenerative diseases. 17) Memory improvement 38) Neuroprotective effects in vitro 33,35) Aβ clearance in vivo 38) Withanolide A Neurite outgrowth in vitro 18,19) Axonal regeneration and synaptic reconstruction in vitro and in vivo 21) Memory improvement 21) Upregulation of BACE1, ADAM10 and IDE in vitro 31) Withanoside IV Neurite outgrowth in vitro 18,19) Axonal regeneration and synaptic reconstruction in vitro and in vivo 22) Memory improvement 22) Withanoside VI Neurite outgrowth in vitro 18,19) Axonal regeneration and synaptic reconstruction in vitro and in vivo 23) Memory improvement 23) Sominone Axonal regeneration and synaptic reconstruction in vitro 22) Axonal growth in vivo 28) Memory improvement 27) and memory enhancement 28) Denosomin Axonal regeneration and neuroprotective effect in vitro 45) Withanone Neuroprotective effects in vitro 35) Spinal cord injury Withanoside IV Axonal growth in vivo and functional recovery 43) Denosomin Axonal growth in vivo and functional recovery 45) Parkinson's disease Extract Anti-oxidant effect in vivo [55][56][57][58][59] Neuroprotective effect in vivo 55,59) Functional recovery [55][56][57][58][59] Huntington's disease Extract Anti-oxidant ef...…”

Withania somniferaphytochemicals confer neuroprotection by selective inhibition of nNos: Anin silicostudy to search potent and selective inhibitors for human nNOS

“…eNOS and iNOS. Previously, many studies have reported that plant extracts of WS and its constituents could be developed as a neurotherapeutic drug for Alzheimer's disease, 50 Parkinson's disease, 51 pentylenetetrazol seizure, 52 ischemic stroke, 53 schizophrenia, 54 cerebral ischemia, 55 anxiety, 56 and stress. 57 Also, confer neuroprotection from nNOS-mediated neurodegeneration by binding in the heme-active site with higher a±nity than its substrate and 14j inhibitor as well as selectively inhibit the nNOS (Fig.…”

Chemistry and pharmacology of withania somnifera: An update

“…W. somnifera and its bioactive withanolides are also effective in treating Parkinson's disease, where it was revealed that its root extract enhances brain dopamine level in Parkinson's animals and also improves physiological abnormalities seen in Parkinson's disease. W. somnifera improves the condition of lipidperoxidation, reduced glutathione content, activities of glutathione-S-transferase, glutathione reductase, glutathione peroxidase, superoxide dismutase and catalase, catecholamine content, dopaminergic D2 receptor binding affinity and tyrosine hydroxylase expression (RajaSankar et al, 2009). Supplement with L-Dopa W. somnifera were also effective in inhibiting haloperidolinduced catalepsy in mice (Girdhari et al, 2009).…”